NCT00443014

Brief Summary

The Dementia Study in Northern Norway is an open controled intervention trial carried out in nine rural municipalities, five of which allocated to intervention and four to control. A RCT with donepezil and placebo is superimposed on all patients included in the study. In this way the study has a 2x2 factorial design. The outcome measures are changes in cognitive performance and ADL function measured by standardized cognitive and neuropsychological tests every four months during a one-year follow-up. The main goal of this study is to examine the effect of systematically and individually adjusted stimulation therapy on cognitive function in patients having recent diagnoses of Alzheimer´s disease (AD). A secondary goal is to examine whether or not ChEI has an additional effect on cognitive function superimposed on stimulation therapy. From January 2006 to 31th March 2008 187 patients with a recent diagnosis of dementia were included. Patients were recruited by GPs in routine practice (n=87) and by a population based screening (n=100).Screening recruited younger patients with a higher MMSE-score, and relatively more men. All over, women were older and at a more serious disease stage. After age adjusting significantly more women were living single and required more supports from the community nursery.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
187

participants targeted

Target at P75+ for phase_4 alzheimer-disease

Timeline
Completed

Started Jun 2003

Longer than P75 for phase_4 alzheimer-disease

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2003

Completed
3.8 years until next milestone

First Submitted

Initial submission to the registry

March 2, 2007

Completed
3 days until next milestone

First Posted

Study publicly available on registry

March 5, 2007

Completed
2.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2009

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2009

Completed
Last Updated

November 10, 2011

Status Verified

November 1, 2011

Enrollment Period

6 years

First QC Date

March 2, 2007

Last Update Submit

November 9, 2011

Conditions

Keywords

Stimulation therapyAcetylcholinesterase inhibitorsSynergetic

Outcome Measures

Primary Outcomes (1)

  • The cognitive function is measured with the Alzheimer's Disease Assessment

    Every fourth month in one year

Secondary Outcomes (1)

  • Changes in Activity of Daily Living (ADL) measured by standardized tests.

    When the patient is included and after one year

Study Arms (2)

A Cognitive stimulation therapy

EXPERIMENTAL

Patients with recently diagnosed dementia in five of the study municipality.

Device: Cognitive, physical and social stimulation

B Care as usual

NO INTERVENTION

Interventions

Sessions of 30 minutes daily five days a week for one year

A Cognitive stimulation therapy

Eligibility Criteria

Age65 Years+
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)

You may qualify if:

  • Subject aged 65-94 years with a recent diagnosed AD and without any contraindications for the use of donepezil.
  • A MMSE sum score has to be at least10 points

You may not qualify if:

  • Behavioural disturbance which make cooperation and cognitive testing impossible.
  • Individuals with reduced approval competence expressing any reluctance to participate are excluded, as well as those not understanding the purpose of the study and who have relatives or care givers disapproving participation.
  • Individuals having a diagnosis of dementia treated with CheI at entry are also excluded.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Arran Lulesami Centre

Drag, Nordland, 8270, Norway

Location

Related Publications (3)

  • Graff MJ, Vernooij-Dassen MJ, Thijssen M, Dekker J, Hoefnagels WH, Rikkert MG. Community based occupational therapy for patients with dementia and their care givers: randomised controlled trial. BMJ. 2006 Dec 9;333(7580):1196. doi: 10.1136/bmj.39001.688843.BE. Epub 2006 Nov 17.

    PMID: 17114212BACKGROUND
  • Andersen F, Viitanen M, Halvorsen DS, Straume B, Wilsgaard T, Engstad TA. The effect of stimulation therapy and donepezil on cognitive function in Alzheimer's disease. A community based RCT with a two-by-two factorial design. BMC Neurol. 2012 Jul 19;12:59. doi: 10.1186/1471-2377-12-59.

  • Andersen F, Engstad TA, Straume B, Viitanen M, Halvorsen DS, Hykkerud S, Sjobrend K. Recruitment methods in Alzheimer's disease research: general practice versus population based screening by mail. BMC Med Res Methodol. 2010 Apr 29;10:35. doi: 10.1186/1471-2288-10-35.

Related Links

MeSH Terms

Conditions

Alzheimer Disease

Interventions

Physical Examination

Condition Hierarchy (Ancestors)

DementiaBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesTauopathiesNeurodegenerative DiseasesNeurocognitive DisordersMental Disorders

Intervention Hierarchy (Ancestors)

Diagnostic Techniques and ProceduresDiagnosis

Study Officials

  • Fred Andersen, MD GP

    University of Northern Norway

    PRINCIPAL INVESTIGATOR
  • Torgeir Engstad, MD, PhD

    University of Northern Norway

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
FACTORIAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 2, 2007

First Posted

March 5, 2007

Study Start

June 1, 2003

Primary Completion

June 1, 2009

Study Completion

June 1, 2009

Last Updated

November 10, 2011

Record last verified: 2011-11

Locations